WE INVEST IN LIFE

Ridgeline, a Versant Ventures Discovery Engine located in Switzerland, creates new biotech companies in partnership with entrepreneurs, industry and leading academics across Europe.

ABOUT US

Ridgeline, a Versant Ventures Discovery Engine, creates and operates Versant-financed innovative biotech companies in partnership with entrepreneurs, industry, and leading academics across Europe. In recent years, Ridgeline has assembled an international team of highly experienced drug discovery and industry professionals and built and operated multiple new successful companies; these companies have raised significant funds through Series B, IPO, Pharma Partnerships and an exit through a trade sale.

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $3.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 75 Versant companies have achieved successful acquisitions or IPOs. Versant is currently investing out of its seventh fund, Versant Venture Capital VII, a $600 million global biotech fund closed in December 2018. In parallel the firm co-invests out of its Canadian strategic fund Versant Voyageurs I and its later-stage biotech opportunity fund Versant Vantage I. For more information, please visit www.versantventures.com.

VERSANT DISCOVERY ENGINES

Accessing the best science and innovation

RIDGELINE - A VERSANT VENTURES DISCOVERY ENGINE

DISCOVER

Ridgeline is rapidly developing the foundational science and technology of our new companies. Our goal is to grow these newcos into leading biotechs.

SOURCE

We partner with entrepreneurs and leading academics across Europe to access breakthrough transformational science that serves as the foundation of our company creation efforts.

DISCOVER

Together with our academic founders, our international team of accomplished industry R&D veterans drives research to create novel platforms and high-quality therapeutic candidates.

BUILD

Our international team has deep investment, research and operating experience that enables an efficient, hands-on approach to company building and value creation.

RIDGELINE BUILDS
COMPANIES

Ridgeline is a Versant Ventures Discovery Engine. Founded in 2017, Ridgeline has the mission to build new leading biotech companies, operate them, help them to grow and establish their own independent footprint. These include Black Diamond Therapeutics, Bright Peak Therapeutics, and Monte Rosa Therapeutics which operate fully independently. Several more recently founded companies, including Cimeio Therapeutics, Red Ridge Bio, and SixPeaks Bio are operating in collaboration with Ridgeline.

VIEW RIDGELINE-BUILT COMPANIES